Advertisement

Topics

Genentech’s Tecentriq Receives FDA Approval for Treatment of a Specific Type of Metastatic Lung Cancer

09:22 EDT 19 Oct 2016 | Speciality Pharma Journal

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted …

Original Article: Genentech’s Tecentriq Receives FDA Approval for Treatment of a Specific Type of Metastatic Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Tecentriq Receives FDA Approval for Treatment of a Specific Type of Metastatic Lung Cancer"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...